1 - 10 out of 388Page size: 10
  1. 2022

  2. Cell environment shapes TDP-43 function with implications in neuronal and muscle disease

    NYGC ALS Consortium, 1 Dec 2022, In: Communications Biology. 5, 1, 314.

    Research output: Contribution to journal › Article › Academic › peer-review

  3. Effect of NOTCH3 EGFr Group, Sex, and Cardiovascular Risk Factors on CADASIL Clinical and Neuroimaging Outcomes

    Hack, R. J., Cerfontaine, M. N., Gravesteijn, G., Tap, S., Hafkemeijer, A., van der Grond, J., Witjes-Ané, M-N., Baas, F., Rutten, J. W. & Lesnik Oberstein, S. A. J., 1 Oct 2022, In: Stroke. 53, 10, p. 3133-3144 12 p.

    Research output: Contribution to journal › Article › Academic › peer-review

  4. Therapeutic Intervention with Anti-Complement Component 5 Antibody Does Not Reduce NASH but Does Attenuate Atherosclerosis and MIF Concentrations in Ldlr-/-.Leiden Mice

    Seidel, F., Kleemann, R., van Duyvenvoorde, W., van Trigt, N., Keijzer, N., van der Kooij, S., van Kooten, C., Verschuren, L., Menke, A., Kiliaan, A. J., Winter, J., Hughes, T. R., Morgan, B. P., Baas, F., Fluiter, K. & Morrison, M. C., 14 Sep 2022, In: International journal of molecular sciences. 23, 18, 10736.

    Research output: Contribution to journal › Article › Academic › peer-review

  5. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A

    NYGC ALS Consortium, 3 Mar 2022, In: Nature. 603, 7899, p. 131-137 7 p.

    Research output: Contribution to journal › Article › Academic › peer-review

  6. Development, Characterization, and in vivo Validation of a Humanized C6 Monoclonal Antibody that Inhibits the Membrane Attack Complex

    Gytz Olesen, H., Michailidou, I., Zelek, W. M., Vreijling, J., Ruizendaal, P., de Klein, F., Marquart, J. A., Kuipers, T. B., Mei, H., Zhang, Y., Ahasan, M., Johnson, K. K., Wang, Y., Morgan, B. P., van Dijk, M., Fluiter, K., Andersen, G. R. & Baas, F., 2022, (E-pub ahead of print) In: Journal of innate immunity.

    Research output: Contribution to journal › Article › Academic › peer-review

  7. NOS1AP is a novel molecular target and critical factor in TDP-43 pathology

    NYGC ALS Consortium, 2022, In: Brain Communications. 4, 5

    Research output: Contribution to journal › Article › Academic › peer-review

  8. Pathogenic variants in three families with distal muscle involvement

    Weterman, M. A. J., Bronk, M., Jongejan, A., Hoogendijk, J. E., Krudde, J., Karjosukarso, D., Goebel, H. H., Aronica, E., Jöbsis, G. J., van Ruissen, F., van Spaendonck-Zwarts, K. Y., de Visser, M. & Baas, F., 2022, (E-pub ahead of print) In: Neuromuscular disorders.

    Research output: Contribution to journal › Article › Academic › peer-review

  9. Tackling Neuroinflammation After Traumatic Brain Injury: Complement Inhibition as a Therapy for Secondary Injury

    van Erp, I. A. M., Michailidou, I., van Essen, T. A., van der Jagt, M., Moojen, W., Peul, W. C., Baas, F. & Fluiter, K., 2022, (E-pub ahead of print) In: Neurotherapeutics.

    Research output: Contribution to journal › Article › Academic › peer-review

  10. 2021

  11. Assembly defects of human tRNA splicing endonuclease contribute to impaired pre-tRNA processing in pontocerebellar hypoplasia

    Sekulovski, S., Devant, P., Panizza, S., Gogakos, T., Pitiriciu, A., Heitmeier, K., Ramsay, E. P., Barth, M., Schmidt, C., Tuschl, T., Baas, F., Weitzer, S., Martinez, J. & Trowitzsch, S., 1 Dec 2021, In: Nature communications. 12, 1, 5610.

    Research output: Contribution to journal › Article › Academic › peer-review

  12. Safety and efficacy of C1-inhibitor in traumatic brain injury (CIAO@TBI): study protocol for a randomized, placebo-controlled, multi-center trial

    van Erp, I. A. M., van Essen, T. A., Fluiter, K., van Zwet, E., van Vliet, P., Baas, F., Haitsma, I., Verbaan, D., Coert, B., de Ruiter, G. C. W., Moojen, W. A., van der Jagt, M. & Peul, W. C., 1 Dec 2021, In: Trials. 22, 1, 874.

    Research output: Contribution to journal › Article › Academic › peer-review

Previous 1 2 3 4 5 6 7 8 ...39 Next

ID: 115955